A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Panobinostat (Primary) ; Sirolimus; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 30 Mar 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 30 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 12 Dec 2017 Results (n=27) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology